Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash & Equivalents (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Cash & Equivalents for 4 consecutive years, with $132.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 55.31% to $132.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $132.8 million through Dec 2025, down 55.31% year-over-year, with the annual reading at $132.8 million for FY2025, 55.31% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $132.8 million at Phathom Pharmaceuticals, down from $135.2 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $384.3 million in Q4 2023, with the low at $130.1 million in Q1 2023.
  • Average Cash & Equivalents over 4 years is $221.8 million, with a median of $210.1 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 149.92% in 2024, then plummeted 59.96% in 2025.
  • Over 4 years, Cash & Equivalents stood at $155.9 million in 2022, then surged by 146.49% to $384.3 million in 2023, then decreased by 22.64% to $297.3 million in 2024, then plummeted by 55.31% to $132.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $132.8 million, $135.2 million, and $149.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.